Mr Pearce is a Melbourne-based entrepreneur with over three decades of business experience.
Mr Pearce esablished Pearce Pharmaceuticals, a trading company in raw materials for the drug and veterinarian industries as well as packaging for the cosmetics and beauty industry. Mr Pearce expanded this business to create and own Scental Pacific Pty Ltd, a full service contract manufacturer servicing the bath, body and beauty industry. He grew this business to a turnover of over $25 million and in excess of 150 staff. In 1996 Mr Pearce sold Scental Pacific Pty Ltd to the Smorgan family while retaining and expanding his Pearce Pharmaceuticals trading business into the Continental Group. In 2002, Mr Pearce re-established himself as a contract manufacturer in the bath and beauty industry with the acquisition of a small factory. In 2010, he renamed that business as Beautiworx. In 2014, Mr Pearce sold Beautiworx into a company where he was one of the two major shareholders, CEO of the manufacturing arm and a director on the Board. This company, BWX Limited, was successfully listed on the ASX in 2015 with a current market capitalisation of over $400 million being a Brand business vertically integrated with manufacturing and distribution.
Mr Morton holds a Bachelor of Economics, a Graduate Diploma in Financial Management and is a member of the Institute of Chartered Accountants of Australia and New Zealand. Mr Morton is also a Responsible Manager under the Australian Securities and Investment Commission and a Responsible Executive under the Financial Services Authority United Kingdom.
Mr Morton has over thirty years experience as a senior executive in investment banking and roles with KPMG, Bain and Company, HSBC and as CEO of a London-based stock broker. More recently, Mr Morton was CEO of a UK-based Investment group with a focus on global investments in pre-IPO and small to mid capitalisation companies in the technology, biotechnology and healthcare sectors.
Qualifications: B.Ec., Grad. Dip. Financial Management, CA ANZ.
Mr Lan joined the Probiotec board in February 2017. Mr Lan was the founding Managing Director of Sydney-based pharmaceutical company Aspen Pharmacare Australia, a subsidiary of South African listed Aspen Pharmacare Holdings. During Mr Lan's tenure, Aspen Australia experienced exponential growth, particularly after the acquisition of Sigma's branded and generics portfolio in 2011 (as well as its manufacturing facilities), and is today one of Australia's largest pharmaceutical companies, with a diverse portfolio of over 260 products covering prescription and OTC. When Mr Lan retired after 15 years with the company, Aspen's Asia Pacific operations (including Australia) had annualised sales in excess of $1 billion.
Prior to joining Aspen, Mr Lan has had extensive experience working in the pharmaceutical industry internationally, including senior roles with Ciba-Geigy (now Novartis) in Switzerland and Saudi Arabia, as well as with Sanofi-Aventis in Australia. Mr Lan holds an MBA from the University of Michigan.
Prior to joining Probiotec, Wesley was employed by KPMG in Taxation and Finance. He has also worked internationally for Deutsche Bank and BNP Paribas Investment Bank in London.
Qualifications: B.Comm (Accounting, Finance), LLB (hons), CPA.